ANASCORP (Rare Disease Therapeutics, Inc)


Welcome to the PulseAid listing for the ANASCORP drug offered from Rare Disease Therapeutics, Inc. This Antivenin [EPC],Passively Acquired Immunity [PE],Venom Neutralization [MoA],Antivenins [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
LABELER NAME / MANUFACTURER: Rare Disease Therapeutics, Inc
NON-PROPRIETARY NAME: CENTRUROIDES (Scorpion) IMMUNE F(ab)2 (EQUINE)
SUBSTANCE NAME: CENTRUROIDES FAB2 ANTIVENIN (EQUINE)
TYPE: PLASMA DERIVATIVE
PHARMA CLASS: Antivenin [EPC],Passively Acquired Immunity [PE],Venom Neutralization [MoA],Antivenins [Chemical/Ingredient]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2011-08-03
END MARKETING DATE: 0000-00-00


ANASCORP PLASMA DERIVATIVE Details:

Item DescriptionANASCORP from Rare Disease Therapeutics, Inc
LABELER NAME: Rare Disease Therapeutics, Inc
DEA SCHEDULE:
ACTIVE STRENGTH: 24(mg/mL)
START MARKETING DATE: 2011-08-03
END MARKETING DATE: 0000-00-00
PRODUCT ID: 66621-0150_c8f00dc0-684c-4389-86d5-b566709205f1
PRODUCT NDC: 66621-0150
APPLICATION NUMBER: BLA125335

Other CENTRUROIDES FAB2 ANTIVENIN (EQUINE) Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Rare Disease Therapeutics, IncANASCORP